Ann: Quarterly Activity Report & Appendix 4C, page-37

Seems like a lot of weirdly negative sentiment floating around, given we have dozens of in-progress line items and new developments just revealed or updated. The amount of work being accomplished is impressive - and the KOLs and orgs getting involved cannot be undersold. This is big boy pants stuff.

To those looking for the dollar signs and rocket emojis:

A commercial transaction can happen at any point from here. I'll say that again:

A commercial transaction can happen at any point from here.

RAC is being looked at. Of course we are.

Nothing about progressing preclinical work makes us any less attractive to early offers - and, if anything, the breadth of work being conducted around the world (and, particularly in the USA) tells me that much of what we've begun is in place to be smoothly transitioned if and when transactions do occur. Just because we've set these targets in front of us on the timeline does not mean Race Oncology will be the entity to see them through at the finish line.

The carve out here is, the more clinical data we have on our books, the higher the value of the IP to potential suitors.

Again, a commercial transaction can happen at any point from here. The next nine months will tell all.